CUDC-907

Known as: PI3K/HDAC Inhibitor CUDC-907 
An orally bioavailable inhibitor of both phosphoinositide 3-kinase (PI3K) class I and pan histone deacetylase (HDAC) enzymes, with potential… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2016
01220122016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Upregulation of MYC is a common driver event in human cancers, and some tumors depend on MYC to maintain transcriptional programs… (More)
Is this relevant?
2017
2017
The role of bone marrow adipocytes (BMAs) in overall energy metabolism and their effects on bone mass are currently areas of… (More)
Is this relevant?
2017
2017
Purpose: There is currently no standard therapy for anaplastic thyroid cancer (ATC) and poorly differentiated thyroid cancer… (More)
Is this relevant?
2017
2017
BACKGROUND/AIMS 5-Fluorouracil (5-FU) is widely used in the treatment of patients with colorectal cancer (CRC). However, the… (More)
Is this relevant?
2017
2017
Platinum (Pt)-based anticancer drugs are the mainstay of treatment for solid cancers. However, resistance to Pt drugs develops… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2017
2017
CUDC-907 is a first-in-class, oral small molecule inhibitor of both HDAC (class I and II) and PI3K (class Iα, β, and δ) enzymes… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
2017
2017
Phosphoinositide 3-kinase (PI3K) and Myc are known to cooperate in promoting the survival and growth of a variety of B-cell… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
BACKGROUND Treatment options for patients with relapsed or refractory lymphoma and multiple myeloma are limited. CUDC-907 is an… (More)
Is this relevant?
2016
2016
CUDC-907 is a novel, dual-acting small molecule compound designed to simultaneously inhibit the activity of histone deacetylase… (More)
Is this relevant?
2012
2012
PURPOSE Given that histone deacetylase (HDAC) inhibitors are known to induce multiple epigenetic modifications affecting… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?